Helius Medical Technologies

Other, 642 Newtown Yardley Road, Newtown, Pennsylvania, 18940, United States, 11-50 Employees

Phone Number: +18*********

Who is HELIUS MEDICAL TECHNOLOGIES

Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brains a...

Get Full Access

Headquarters: 642 Newtown Yardley Road, Newtown, Pennsylvania, 18940, United States
Date Founded: 2014
Employees: 11-50
Revenue: $5 Million to $10 Million
Active Tech Stack: See technologies

Industry: Other

SIC Code: 3845 | NAICS Code: 334510 | Show More

Does something look wrong? Fix it. | View contact records from HELIUS MEDICAL TECHNOLOGIES

Helius Medical Technologies Org Chart and Mapping

Employees

Michelle Carlisi

Director of Marketing, North America

Email
Phone

Lola Abhulimen

Senior Director Clinical Operations

Email
Phone

Abou Camara

Financial Planning and Analysis Manager

Email
Phone

See Full Org Chart

View Email Formats for Helius Medical Technologies

You are signed out

Join Now

Free credits every month

Frequently Asked Questions Regarding Helius Medical Technologies

Answer: Helius Medical Technologies's headquarters are located at 642 Newtown Yardley Road, Newtown, Pennsylvania, 18940, United States

Answer: Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brains ability to compensate and promotes neuroplasticity, aiming to improve the lives of people dealing with neurologic diseases. The Companys first commercial product is the Portable Neuromodulation Stimulator (PoNS). PoNSTM, short for Portable Neuromodulation Stimulator, is an innovative medical device. It is inclusive of a controller and mouthpiece, that delivers mild stimulation to the surface of the tongue. This stimulation triggers a flow of neural impulses to the brain structures that control balance and gait. PoNS is meant to be used in conjunction with supervised therapeutic activity, referred to as, PoNS TherapyTM. Use of the device while engaging in movement and coordination tasks promotes neuromodulation, activating brain pathways to help improve balance and gait. PoNS is authorized in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (MS) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. PoNS is authorized in Canada for three indications: (i) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (mmTBI) and is to be used in conjunction with physical therapy; and (ii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke, to be used in conjunction with physical therapy. PoNS is authorized in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait.